Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials | BMC Cancer User montaukwhaler, in the non small cell lung cancer subreddit, 30 Apr 2019